UroMems SAS
Medical technology company developing smart active implantable devices to treat stress urinary incontinence (SUI). The company designs and prototypes mechatronic, MEMS-based implantable systems with embedded sensors and algorithms, conducts preclinical and early clinical feasibility studies, and engages with European and U.S. regulators in preparation for pivotal trials and commercialization.
Industries
Nr. of Employees
small (1-50)
UroMems SAS
5 Rue Raymond Chanas 38320 Eybens France
Patents
System and method for detecting an endo-urethral device for an artificial sphincter that is implantable in an animal or human body
US-11612354-B2
View Details
System and method for detecting an endo-urethral device for an artificial sphincter that is implantable in an animal or human body
US-11612354-B2
View DetailsProducts
Smart automated implantable artificial urinary sphincter (prototype)
An active implantable system that uses on-board sensors, embedded algorithms and mechatronic actuation to adjust urethral compression in response to patient activity for treatment of stress urinary incontinence.
Smart automated implantable artificial urinary sphincter (prototype)
An active implantable system that uses on-board sensors, embedded algorithms and mechatronic actuation to adjust urethral compression in response to patient activity for treatment of stress urinary incontinence.
Services
Design and conduct of first-in-human and multicenter feasibility clinical studies to evaluate implant safety and performance.
Prototyping, refinement and preparation for production of complex implantable devices, including industrialization activities.
Design and conduct of first-in-human and multicenter feasibility clinical studies to evaluate implant safety and performance.
Prototyping, refinement and preparation for production of complex implantable devices, including industrialization activities.
Expertise Areas
- Implantable device development
- Mechatronics and MEMS
- Embedded software and algorithm development
- Clinical trial management and feasibility studies
Key Technologies
- Microelectromechanical systems (MEMS)
- Embedded systems
- On-board micro-sensors
- Closed-loop control algorithms
News & Updates
Scheduled presence at SUFU, EAU and AUA conferences to present clinical data and engage clinical community.
Multiple presentations and publications reporting first-in-human and animal safety data, including SOPHIA study results and RAM2 animal safety study.
Completed the first-in-man feasibility cohort with successful six-month primary endpoints and positive secondary outcomes in male patients, supporting design of pivotal trials.
Received STeP designation from the U.S. Food and Drug Administration to support development pathway for the implantable system.
Awarded funding from the EIC Accelerator program to support pivotal SUI trials in the U.S. and Europe.
Secured Series C funding to support pivotal clinical trials.
Scheduled presence at SUFU, EAU and AUA conferences to present clinical data and engage clinical community.
Multiple presentations and publications reporting first-in-human and animal safety data, including SOPHIA study results and RAM2 animal safety study.
Completed the first-in-man feasibility cohort with successful six-month primary endpoints and positive secondary outcomes in male patients, supporting design of pivotal trials.
Received STeP designation from the U.S. Food and Drug Administration to support development pathway for the implantable system.
Awarded funding from the EIC Accelerator program to support pivotal SUI trials in the U.S. and Europe.
Secured Series C funding to support pivotal clinical trials.